Taxol in malignant melanoma.

P. H. Wiernik, Avi Israel Einzig

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

Taxol is a major new antitumor agent with significant activity against a number of human cancers. Preclinical investigation demonstrated significant activity against B16 melanoma and against cells derived from melanoma in a human stem cell assay. To determine whether there are sufficient clinical phase II data for Taxol activity against melanoma to warrant phase III clinical trials, data from the three published trials of Taxol in patients with metastatic malignant melanoma plus data from an ongoing Albert Einstein Cancer Center study of Taxol plus granulocyte-colony stimulating factor were analyzed for response rate and quality. Of 73 evaluable patients, complete plus partial responses occurred in 12 (16.4%). An additional nine patients had objective responses not qualifying for partial response, and 10 others had stabilization of previously progressive disease. Two complete responders remain disease free at 33+ and 46+ months. Patients with stable disease, minimal response, or partial response had a median duration of response of approximately 5 months (range 1-17 months). Responses occurred in liver, lung, skin, and other tissues. Taxol as a single agent has activity comparable with that of dacarbazine, cisplatin, or interleukin-2 in metastatic malignant melanoma. Pilot studies of Taxol combinations are warranted.

Original languageEnglish (US)
Pages (from-to)185-187
Number of pages3
JournalJournal of the National Cancer Institute. Monographs
Issue number15
StatePublished - Dec 1 1993

Fingerprint

Paclitaxel
Melanoma
Colony-Forming Units Assay
Dacarbazine
Phase III Clinical Trials
Experimental Melanomas
Granulocyte Colony-Stimulating Factor
Antineoplastic Agents
Cisplatin
Interleukin-2
Neoplasms
Lung
Skin
Liver

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Taxol in malignant melanoma. / Wiernik, P. H.; Einzig, Avi Israel.

In: Journal of the National Cancer Institute. Monographs, No. 15, 01.12.1993, p. 185-187.

Research output: Contribution to journalReview article

@article{5eff022a5ab54d618fdb7ef8af4249b9,
title = "Taxol in malignant melanoma.",
abstract = "Taxol is a major new antitumor agent with significant activity against a number of human cancers. Preclinical investigation demonstrated significant activity against B16 melanoma and against cells derived from melanoma in a human stem cell assay. To determine whether there are sufficient clinical phase II data for Taxol activity against melanoma to warrant phase III clinical trials, data from the three published trials of Taxol in patients with metastatic malignant melanoma plus data from an ongoing Albert Einstein Cancer Center study of Taxol plus granulocyte-colony stimulating factor were analyzed for response rate and quality. Of 73 evaluable patients, complete plus partial responses occurred in 12 (16.4{\%}). An additional nine patients had objective responses not qualifying for partial response, and 10 others had stabilization of previously progressive disease. Two complete responders remain disease free at 33+ and 46+ months. Patients with stable disease, minimal response, or partial response had a median duration of response of approximately 5 months (range 1-17 months). Responses occurred in liver, lung, skin, and other tissues. Taxol as a single agent has activity comparable with that of dacarbazine, cisplatin, or interleukin-2 in metastatic malignant melanoma. Pilot studies of Taxol combinations are warranted.",
author = "Wiernik, {P. H.} and Einzig, {Avi Israel}",
year = "1993",
month = "12",
day = "1",
language = "English (US)",
pages = "185--187",
journal = "NCI Monographs",
issn = "1052-6773",
publisher = "Oxford University Press",
number = "15",

}

TY - JOUR

T1 - Taxol in malignant melanoma.

AU - Wiernik, P. H.

AU - Einzig, Avi Israel

PY - 1993/12/1

Y1 - 1993/12/1

N2 - Taxol is a major new antitumor agent with significant activity against a number of human cancers. Preclinical investigation demonstrated significant activity against B16 melanoma and against cells derived from melanoma in a human stem cell assay. To determine whether there are sufficient clinical phase II data for Taxol activity against melanoma to warrant phase III clinical trials, data from the three published trials of Taxol in patients with metastatic malignant melanoma plus data from an ongoing Albert Einstein Cancer Center study of Taxol plus granulocyte-colony stimulating factor were analyzed for response rate and quality. Of 73 evaluable patients, complete plus partial responses occurred in 12 (16.4%). An additional nine patients had objective responses not qualifying for partial response, and 10 others had stabilization of previously progressive disease. Two complete responders remain disease free at 33+ and 46+ months. Patients with stable disease, minimal response, or partial response had a median duration of response of approximately 5 months (range 1-17 months). Responses occurred in liver, lung, skin, and other tissues. Taxol as a single agent has activity comparable with that of dacarbazine, cisplatin, or interleukin-2 in metastatic malignant melanoma. Pilot studies of Taxol combinations are warranted.

AB - Taxol is a major new antitumor agent with significant activity against a number of human cancers. Preclinical investigation demonstrated significant activity against B16 melanoma and against cells derived from melanoma in a human stem cell assay. To determine whether there are sufficient clinical phase II data for Taxol activity against melanoma to warrant phase III clinical trials, data from the three published trials of Taxol in patients with metastatic malignant melanoma plus data from an ongoing Albert Einstein Cancer Center study of Taxol plus granulocyte-colony stimulating factor were analyzed for response rate and quality. Of 73 evaluable patients, complete plus partial responses occurred in 12 (16.4%). An additional nine patients had objective responses not qualifying for partial response, and 10 others had stabilization of previously progressive disease. Two complete responders remain disease free at 33+ and 46+ months. Patients with stable disease, minimal response, or partial response had a median duration of response of approximately 5 months (range 1-17 months). Responses occurred in liver, lung, skin, and other tissues. Taxol as a single agent has activity comparable with that of dacarbazine, cisplatin, or interleukin-2 in metastatic malignant melanoma. Pilot studies of Taxol combinations are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0027829630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027829630&partnerID=8YFLogxK

M3 - Review article

SP - 185

EP - 187

JO - NCI Monographs

JF - NCI Monographs

SN - 1052-6773

IS - 15

ER -